E. Ahern
12 Papers
6 Citations
E. Ahern is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 12 publications.
Chat about Author
Papers
Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment
E. Ahern,Teresa Brown,Louise Campbell,Brett G.M. Hughes,Merrilyn Banks,Charles Y. Lin,Lizbeth Kenny,J. M. Bauer +7 more
TL;DR: Overall, rates of myosteatosis were high at both pre- and post-treatment timepoints, and Post-treatment sarcopenia was associated with worse five-year overall survival, as was post- treatment sarc Openia in those who had myost Eatosis.
9
Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers
J. Dunn,Robert McCuaig,Abel Tan,Wenjuan Tu,Fan Wu,Kylie M. Wagstaff,Anjum Zafar,Sayed Abdel Raheem Sayed Ali,Himanshu Diwakar,Jane E. Dahlstrom,Elaine G. Bean,Jade K. Forwood,Sofiya Tsimbalyuk,Emily M. Cross,Kristine Hardy,Amanda L. Bain,E. Ahern,Riccardo Dolcetti,Roberta Mazzieri,Desmond Yip,Melissa Eastgate,Laeeq Malik,Peter J. Milburn,David A. Jans,Sudha Rao +24 more
TL;DR: A novel PKC-θ inhibitor is presented that specifically inhibits nuclear translocation of PKC -θ without interrupting normal signaling in healthy T cells, and is shown to mediates immunotherapy resistance via its activity in circulating tumor cells and dysfunctional CD8+ T cells.
Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)
Amy Body,E. Ahern,Luxi Lal,Karen Gillett,H. Abdulla,Stephen Opat,Tracey A. O'Brien,Peter Downie,Stuart Turville,C Mee Ling Munier,Corey Smith,C. Raina MacIntyre,Eva Segelov +12 more
TL;DR: SerOzNET as discussed by the authors is a prospective observational study of adults and children with cancer undergoing routine SARS-CoV-2 vaccination in Australia, where peripheral blood will be collected and processed at five timepoints for analysis of serologic responses to vaccine and exploration of T-cell immune correlates.
1611P Clinical determinants of SARS-CoV-2 vaccine response in adults with cancer
Eva Segelov,Amy Body,L. Lal,H. Abdulla,Stuart Turville,Zayar Naing,Stephen Opat,Mark Leahy,J. Balendra,Narmin R. Hamad,Robert McCuaig,S. Rao,Katie E. Lineburg,C. Smith,C. Raina MacIntyre,Vivienne E. Milch,L. Busija,E. Ahern +17 more
TL;DR: This paper showed initial response to COVID-19 vaccination in most patients (pts) with solid cancer, many with haematological (haem) cancer remain vulnerable and data beyond initial response and regarding effect of booster doses are lacking.
1
Rapid Protocol Development, Study Startup and Enrolment of a Prospective Study of COVID-19 Vaccination for Patients with Cancer: A Collaborative Approach
Amy Body,Vivienne E. Milch,Lynda M McSorley,Luxi Lal,E. Ahern,Regina Ryan,G. Jones,Dorothy M. K. Keefe,Eva Segelov +8 more
TL;DR: In this article , the authors describe the rapid design and startup of a multicentre study of COVID-19 vaccine response for vulnerable patients with cancer, which is an example of intensive collaboration inspired by the COVID19 pandemic and may serve as an agile research response to real-time public health challenges.